NCT02473536View on ClinicalTrials.gov

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Renal Cell Carcinoma
Interventions
RADIATION

Stereotactic ablative radiation therapy

SABR

Trial Locations (1)

75239

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02473536 - Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC | Biotech Hunter | Biotech Hunter